A peptide derived from spider venom called Ltc2a selectively killed triple-negative breast cancer cells at low concentrations while sparing normal cells, with zebrafish studies confirming low toxicity.
2 μMThe concentration at which the spider venom peptide selectively killed cancer cells while sparing normal cells
What the researchers found
Ltc2a exhibited selective cytotoxicity toward cancer cells compared to normal cells at just 2 μM concentration. The peptide induced rapid cell death within 1 hour in breast cancer cells through membrane disruption, confirmed by propidium iodide staining and scanning electron microscopy showing visible membrane damage.
In vivo zebrafish studies demonstrated favorable peptide uptake with 80% survival at concentrations up to 4 μM, indicating low acute toxicity. Truncated variants of Ltc2a retained their alpha-helical structure and showed preferential uptake in MDA-MB-231 triple-negative breast cancer cells over normal HEK293T cells.
Why it matters
Triple-negative breast cancer is one of the hardest cancers to treat because it lacks the three most common targets for therapy. Finding agents that can selectively kill these cancer cells while sparing healthy tissue is a major unmet need. This study suggests that repurposing venom-derived peptides — originally evolved for microbial defense — could open a new avenue for targeted cancer treatment with potentially fewer side effects than conventional chemotherapy.
How the study worked
The researchers tested the spider venom peptide Ltc2a on triple-negative breast cancer cells (MDA-MB-231) and normal cells (HEK293T) in the lab to assess selective cytotoxicity. They used propidium iodide staining and field emission scanning electron microscopy to visualize membrane disruption. In vivo safety was evaluated in a zebrafish model, and truncated peptide variants were also tested for structural integrity and selective cell uptake.
What this study cannot tell us
This study was conducted in cell cultures and zebrafish, not in mammals or humans, so it remains unclear whether the peptide would work the same way in a human body. The zebrafish model provides only a basic toxicity screen. The study did not evaluate long-term toxicity, pharmacokinetics, or tumor regression in a mammalian cancer model. Additionally, the mechanism of selectivity for cancer cells over normal cells needs further clarification.
How to read the evidence
This is an early-stage preclinical study using cell cultures and a zebrafish model. While the results are promising and well-characterized, the findings have not yet been validated in mammalian models or clinical trials.
When this study was published
Published in 2025, this is very recent research representing the current frontier of venom-derived peptide anticancer therapy.
The bigger picture
This research fits into a growing field exploring animal venom components as sources for new cancer drugs. Venom-derived peptides have evolved over millions of years to interact with cell membranes, making them natural candidates for disrupting the altered membranes of cancer cells. The selective activity shown here supports the broader concept that nature-derived molecules can be repurposed from their original biological roles into targeted therapeutics.
Questions still open
- Would Ltc2a remain selective and effective in mammalian tumor models with a functioning immune system?
- Can the truncated variants be optimized to improve potency while maintaining the favorable safety profile?
- What specific membrane properties of cancer cells make them more susceptible to Ltc2a disruption?
Common questions
What is Ltc2a and where does it come from?
Why is this relevant to triple-negative breast cancer specifically?
Read the original research
Assessing the anticancer potential of spider venom peptide Latarcin Ltc2a against triple negative breast cancer.
Biochimica et biophysica acta. Biomembranes, 1867(7), 184442
Citation
Kaur, Prasanjeet; Roy, Srabaita; Minocha, Shilpi; Chugh, Archana. (2025). Assessing the anticancer potential of spider venom peptide Latarcin Ltc2a against triple negative breast cancer.. Biochimica et biophysica acta. Biomembranes, 1867(7), 184442. https://doi.org/10.1016/j.bbamem.2025.184442